Bon Park

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma.

Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma.

Journal: Blood cancer journal
Published: March 02, 2026

Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed/refractory diffuse large B-cell lymphoma.

Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed/refractory diffuse large B-cell lymphoma.

Journal: Blood advances
Published: April 15, 2025

MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma.

MiR-340-5p regulates PD-L1 and predicts pembrolizumab response in extranodal NK/T-cell lymphoma.

Journal: Scientific reports
Published: November 08, 2024

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma.

Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma.

Journal: Blood
Published: September 30, 2024

Exosomal miR-155-5p drives ibrutinib resistance in B-cell lymphoma.

Exosomal miR-155-5p drives ibrutinib resistance in B-cell lymphoma.

Journal: Experimental cell research
Published: May 20, 2024

Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma.

Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma.

Journal: Annals of laboratory medicine
Published: May 18, 2024

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma.

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma.

Journal: Cancers
Published: October 08, 2022

Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.

Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.

Journal: Cancer research and treatment
Published: January 11, 2022

Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma.

Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma.

Journal: Journal of Cancer
Published: December 01, 2021
Showing 1-9 of 9

Last Updated: 09/26/2026